Seres Therapeutics

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Seres Therapeutics poised for FDA approval with strong pipeline progress

Seres Therapeutics is well-positioned for potential FDA approval of SER-109, backed by strong Phase III efficacy and safety data. The company's financial stability and strategic collaborations underscore a focused approach towards commercial success. Addressing key challenges and leveraging opportunities in product development and market entry will be crucial for Seres Therapeutics' future growth.

Seres Therapeutics secures FDA approval for VOWST, eyes commercial success

Seres Therapeutics is poised for success with FDA approval of VOWST and positive study results for SER-155. The company faces challenges in ensuring consistent engraftment and optimizing operational efficiencies. Opportunities lie in commercializing VOWST and advancing microbiome therapeutics.

Seres Therapeutics reports robust Q2 earnings, eyes VOWST growth

Seres Therapeutics had a strong Q2 2023, propelled by VOWST approval and positive sales performance, positioning the company for continued growth.
While facing challenges like Medicare affordability issues and net losses, Seres remains optimistic about VOWST's potential and profitability trajectory.
By capitalizing on opportunities in education, expansion, and efficiency, Seres aims to drive VOWST adoption, enhance market presence, and achieve financial success.

Seres Therapeutics excels in Q3 with VOWST launch success

Seres Therapeutics reported a strong Q3 performance with the successful VOWST launch, despite a net loss. The company's restructuring focuses on VOWST's growth and long-term sustainability. Challenges include optimizing VOWST sales and navigating reimbursement differences.

Seres Therapeutics excels in 2023 with VOWST launch and financial focus

Seres Therapeutics had a strong 2023, marked by successful product launches, financial discipline, and promising development in microbiome therapeutics.
The company's strengths include innovation, financial stability, strong leadership, and efficient budget management, positioning them for future growth.
Challenges include sustaining momentum, securing funding for advancement, meeting regulatory expectations, and ensuring positive patient experiences.
Opportunities lie in continued growth, partnerships, strategic funding, innovation, and establishing a compelling market narrative.
Overall, Seres Therapeutics is well-positioned for success in the microbiome therapeutics market, with a focus on product development and financial discipline.

Seres Therapeutics reports robust Q1 sales and advances pipeline growth

Seres Therapeutics demonstrated strong sales performance with VOWST net sales reaching $10.1 million in Q1 2024.
The company's focus on commercialization of VOWST and advancement of microbiome therapeutic candidates like SER-155 shows promise for future growth.
Challenges in pricing, inventory management, and funding are being addressed, while opportunities in new patient populations and strategic partnerships are being explored.

Seres Therapeutics sells VOWST assets, reports strong Q2 earnings

Seres Therapeutics' Q2 performance was marked by a strategic asset sale, strong financial results, and progress in key pipeline programs. The company's focus on transformative therapies and data-driven pipeline prioritization positions it well for future growth and impact in the healthcare sector.

Seres Therapeutics reports Q3 loss but sees growth opportunities ahead

Seres Therapeutics faced a net loss in Q3 2024 but maintained strong cash reserves for operations into Q4 2025.
Positive results from SER-155 and the VOWST sale present opportunities for growth and addressing bacterial infections in patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

eFFECTOR Therapeutics Inc

Freight Technologies Inc

Hyzon Motors

TuSimple Holdings

Are you searching for some of the best penny stocks to buy now? I'm sure that if you're reading this article, that's something at the top of your mind.

Best Penny Stocks To Buy? 5 With Big News This Week

CAMBRIDGE, Mass. & HOBOKEN, N.J.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced that VOWST™ (fecal microbiota spores, live-brpk) is now commercially available for patients. VOWST, formerly called SER-109, is the first and only U.S. Food and Drug Administration (FDA)-approved orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI.

Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:00 a.m. ET in New York City. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will b.

Seres Therapeutics to Present at Jefferies Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that the Company has received a $125 million milestone payment from Nestlé Health Science related to the U.S. Food and Drug Administration approval of VOWST™ (fecal microbiota spores, live-brpk), an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibiotic treatment for recurrent CDI. Th.

Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™

Good preliminary results with a second generation product in blood bacterial infections. The Ulcerative Colitis program is still alive.

Seres Q1 Earnings: Major News For Investors

Start Time: 08:30 January 1, 0000 9:18 AM ET Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2023 Earnings Conference Call May 09, 2023, 08:30 AM ET Company Participants Eric Shaff - President and CEO Terri Young - EVP, Chief Commercial and Strategy Officer Lisa von Moltke - EVP and Chief Medical Officer David Arkowitz - EVP, CFO and Head of Business Development David Ege - EVP, Chief Technology Officer Matthew Henn - EVP, Chief Scientific Officer Carlo Tanzi - IR Officer Conference Call Participants Mark Breidenbach - Oppenheimer Joseph Thome - Cowen Tessa Romero - JPMorgan John Newman - Canaccord Genuity Stephen Sloan - Goldman Sachs Keay Nakae - Chardan Capital Markets Operator Hello. My name is Chris, and I will be your conference operator today.

Seres Therapeutics, Inc. (MCRB) Q1 2023 Earnings Call Transcript

Seres Therapeutics (MCRB) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.61 per share a year ago.

Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2023 financial results and provided business updates. “We were thrilled to recently announce the FDA approval of VOWST, the first and only FDA-approved orally administered microbiota-based therapeutic, and with the favorable label indication received from the FDA. Adult recurrent C. difficile infection patients who could benefit from using VOWST, pe.

Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported initial clinical data about SER-155. SER-155 is an oral, cultivated bacterial consortia investigational therapeutic designed to prevent enteric-derived infections and resulting blood stream infections, as well as induce immune tolerance responses to reduce the incidence of graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell.

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

CAMBRIDGE, Mass. & HOBOKEN, N.J.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), and Nestlé Health Science today announced the presentation of data from the Phase 3 open-label ECOSPOR IV study evaluating VOWST (fecal microbiota spores, live-brpk) – the first and only U.S. Food and Drug Administration (FDA)-approved orally administered microbiota-based therapeutic for the prevention of recurrence in adults with recurrent C. difficile (rCDI) following antibacterial treatment. VOWST is.

Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 9, 2023 at 8:30 a.m. ET to discuss first quarter results and provide a general business update, including initial SER-155 Phase 1b safety and pharmacology results from study Cohort 1. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and ref.

Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023

Biotech investing is a wild ride but share prices falling after FDA approval, as has just happened to Seres Therapeutics VOWST product, is pretty weird. On April 26, Seres achieved FDA approval for VOWST (formerly known as SER-109). This is the first FDA approval for an oral microbiomic product, a big deal for the microbiome.

Seres Gets FDA Approval And The Share Price Goes Down!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it has entered into a new $250 million senior secured debt facility (“Term Loan Facility”) provided by funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The Company drew the first tranche of $110 million at closing, with three additional tranches available. These additional tranches include $90 million that will be available in two tranches of.

Seres Therapeutics Announces $250 Million Debt Financing with Oaktree

CAMBRIDGE, Mass. & HOBOKEN, N.J.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced the U.S. Food and Drug Administration (FDA) approval of VOWSTTM (fecal microbiota spores, live-brpk), formerly called SER-109, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). VOWST is not indicated for the treatment of CDI. “Since being f.

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI

Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Iovance Biotherapeutics

Growth stocks fell across the board in 2022. This broad pullback may have created some tremendous buying opportunities.

Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon

Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?

Due to its volatility, Seres Therapeutics, Inc. is a stock that is not for the faint of heart. Seres Therapeutics stock dropped and popped substantially from the outcome of its previous clinical catalysts.

Seres Therapeutics: Binary Catalyst Unlocking

Arrowhead Pharmaceuticals

Biotech stocks, on balance, had a rough 2022. This broad-based sell-off might have created some once-in-a-lifetime buying opportunities.

2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street

Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023 at 8:40 a.m. ET. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website.

Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Carlo Tanzi - IR Officer Eric Shaff - President, CEO & Director Teresa Young - EVP and Chief Commercial & Strategy Officer Lisa von Moltke - EVP & Chief Medical Officer David Arkowitz - EVP, CFO & Head, Business Development David Ege - EVP & CTO Matthew Henn - EVP & Chief Scientific Officer Conference Call Participants Mark Breidenbach - Oppenheimer John Newman - Canaccord Genuity Edward Tenthoff - Piper Sandler & Co. Stephen Sloan - Goldman Sachs Group John Bohnsack - TD Cowen Operator Thank you for holding, and welcome everyone, to the Seres Therapeutics Fourth Quarter 2022 Conference Call. [Operator Instructions].

Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call Transcript

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2022 financial results and provided business updates. “We are eagerly looking forward to the upcoming potential FDA approval of SER-109, an investigational first-in-class oral microbiome therapeutic for recurrent C. difficile infection (rCDI).

Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 7, 2023 at 8:30 a.m. ET to discuss fourth quarter and full year 2022 results and provide a general business update. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4218669.

News for Seres Therapeutics Stock (MCRB)